Related Experiment Videos
Neonatal-onset propionic acidemia: neurologic and developmental profiles, and implications for management
K N North1, M S Korson, Y R Gopal
1Department of Medicine, Children's Hospital, Boston, Massachusetts, USA.
The Journal of Pediatrics
|June 1, 1995
Summary
Current therapy improves survival and nutrition in neonatal-onset propionic acidemia (PA). However, hypotonia and cognitive delays persist, necessitating further treatment advances for better outcomes in PA patients.
Area of Science:
- Biochemistry
- Genetics
- Neurology
Background:
- Propionic acidemia (PA) is an inherited metabolic disorder.
- Neonatal-onset PA presents significant clinical challenges.
Purpose of the Study:
- To document clinical and neurodevelopmental profiles of neonatal-onset PA patients.
- To evaluate the efficacy of current therapies for PA.
Main Methods:
- Prospective evaluation of six PA patients over 15 months.
- Review of historical clinical and biochemical data.
- Assessment of nutritional status, hyperammonemia episodes, and developmental performance.
Main Results:
- Improved survival and nutritional status observed with therapeutic interventions.
- Hypotonia impacted motor development; focal deficits and seizures were absent.
- Mild to moderate intellectual impairment was present in all patients, irrespective of metabolic control.
Conclusions:
- Current PA therapy enhances survival and nutrition, reducing focal neurological deficits.
- Hypotonia and cognitive delays remain challenges even with optimal metabolic control.
- Further therapeutic advancements are crucial for improving developmental and cognitive outcomes in PA.